Spun out of MIT, Organogenesis, Inc. is a longtime established tissue engineering firm focused in regenerative medicine - designing, developing and manufactureing medical products containing living cells and/or natural connective tissue. The company specializes in soft tissue regeneration for use in the areas of bioactive wound healing and oral regeneration. Its products include Apligraf, a living cell-based product indicated for the treatment of venous leg ulcers and diabetic foot ulcers; and GINTUIT, an allogeneic cellularized scaffold product indicated for topical (non-submerged) application to a surgically created vascular wound bed in the treatment of mucogingival conditions in adults. Only minimally SBIR involved, during early years, firm had traded on AMEX (1986-2002) but went into bankruptcy. Re-emerged later and went public again on Nasdaq (Jan 2017). Briefly re-entered SBIR arena in the regenerative medicine space before outgrowing program employment requirements.